Le Lézard
Classified in: Health, Science and technology
Subjects: AWD, PER, WOM, MAT

Evofem Biosciences' CEO Saundra Pelletier Awarded 2019 Business Woman Of The Year


SAN DIEGO, Nov. 14, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier was named a 2019 Business Woman of the Year by the San Diego Business Journal. The publication's annual awards program, hosted Wednesday, November 13, recognized 15 dynamic women business leaders who have contributed significantly to San Diego's workplaces and communities.

(PRNewsfoto/Evofem Biosciences, Inc.)

"I am honored to be recognized among such an accomplished group of women who are making a difference in San Diego and beyond," said Ms. Pelletier. "As a mother, daughter and CEO of a female-forward company developing an innovative new hormone-free, on-demand contraceptive, I am inspired by this tribe of influential female leaders, who are also passionate and selfless role models. Together, we are broadening the definition of leadership and empowering future generations of women to pave their own unique paths forward."

Ms. Pelletier has served as Chief Executive Officer of Evofem Biosciences, Inc. since 2015. During her tenure, she has led the Company through a successful transition to the public market and multiple rounds of equity financing, which have raised in excess of $245 million. She has dedicated her career to advancing women's health and expanding their sexual and reproductive health choices with options that they control.

Winners were selected by an independent judging panel based on their innovation, entrepreneurship, professional accomplishment and community leadership. Of the more than 200 nominations received, 96 were named finalists and 15 women were selected as award winners.

About Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Evofem Biosciences aims to advance the lives of women by developing novel solutions, such as woman-controlled contraception and potential protection from certain sexually transmitted infections. The Company is leveraging its proprietary Multipurpose Vaginal pH Regulator (MVP-Rtm) platform to develop Amphora® (L-lactic acid, citric acid and potassium bitartrate) for hormone-free birth control and prevention of chlamydia. For more information, please visit www.evofem.com.

Amphora® is a registered trademark and Multipurpose Vaginal pH Regulator (MVP-Rtm) is a trademark of Evofem Biosciences, Inc.

Media Contact
Cara Miller
Evofem Biosciences, Inc.
[email protected]
O: (858) 550-1900 x272

 

SOURCE Evofem Biosciences, Inc.


These press releases may also interest you

at 10:05
The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to ResearchAndMarkets.com's offering. Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution deals....

at 10:00
Driving is the leading cause of work-related death each year in the United States, with nearly 40% of deaths on the job occurring on American roads according to the U.S. Bureau of Labor Statistics. A major contributing factor to road deaths each...

at 10:00
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Methimazole Tablets, USP, 5 mg and 10 mg. The Methimazole Tablet market had U.S. sales of approximately $36.8 million for the 12 months ending December 2023 according...

at 10:00
NastLaw LLC announces: If you purchased certain named generic pharmaceutical drugs directly from certain pharmaceutical manufacturers from May 1, 2009 through December 31, 2019, your rights may be affected by proposed class action settlements.A...

at 09:48
Perspire Sauna Studio, one of the country's largest sauna franchises specializing in full spectrum infrared (IR) and red-light therapy (RLT), is rolling out a new sauna design and member experience through the brand's long-standing partnership with...

at 09:38
The Kinetix Group (TKG) and Pfizer Inflammation and Immunology received a PM360 Pharma Choice Award for their recent health equity initiative. The award recognized Pfizer's atopic dermatitis interactive guide for varying skin tones....



News published on and distributed by: